Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in Duchenne muscular dystrophy
NL-OMON52599Phase 3Active, not recruiting
- Sponsor
- University Children's Hospital Basel
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tamoxifen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by University Children's Hospital Basel. Primary endpoints: Change in MFM D1 subscore from baseline to week 48 and Change in MFM D2 subscore from baseline to week 48. Started Nov 2019; status: active, not recruiting.
02
Drugs
tamoxifen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON52599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52599.